In 2021, I wrote a submit on microRNA (miRNA) and hair development. In there, I additionally mentioned messenger RNA (mRNA). And now we have now RNA interference (RNAi) as a hair loss therapy, due to OliX Prescription drugs (South Korea).
Replace: November 22, 2022 — OliX simply revealed preclinical analysis on its androgenetic alopecia therapy program, OLX104C. The outcomes are very encouraging. Precise examine is right here and the researchers demonstrated:
“Efficacy of androgen receptor (AR) discount, hair loss inhibition, and lengthy period of motion in main cultured human follicle dermal papilla cells (HFDPC) and rodent fashions of hair loss.”
They name this know-how “cp-asiRNA concentrating on AR” and “AR-targeting asiRNA (cp-asiAR)”. The asiRNA stands for uneven small interfering RNA.
Replace: Might 27, 2022 — OliX simply raised $45 million and their androgenetic alopecia product (OLX104C) will enter medical trials later this yr.
Replace: August 2021 — OliX will get Discover of Allowance from US Patent and Trademark Workplace for OLX104C.
OliX Prescription drugs RNAi Hair Loss Product OLX104C
OliX Prescription drugs (South Korea) simply made a significant announcement. Their RNAi primarily based hair loss product OLX104C efficiently grew again hair in mice following only one single injection. The mice had been affected by androgenetic alopecia attributable to them being given extra dihydrotestosterone (DHT).
“We’re advancing a novel and doubtlessly sturdy strategy to treating hair loss” — CEO Dong Ki Lee
On this preclinical examine, OLX104C was administered topically to a mouse mannequin by way of an injection. The earlier than and after images are superb. Curiously, they evaluate the outcomes to the anti-androgen Flutamide.
Extra importantly, OliX is the true deal. Their information web page may be very spectacular with common important developments. This consists of elevating $37.2 million in December 2020 (h/t reader “James”). Additionally they obtained US FDA Section 2a approval in November, 2020 to deal with hypertrophic scars.
siRNA
On OliX’s pipeline web page, they state that small interfering RNA (siRNA) has limitations when it comes to stability, supply and toxicity. This isn’t an issue with RNAi therapeutics. Edit: Per the patent, they’re utilizing uneven siRNA to inhibit male sample hair loss gene expression.
Replace: OliX indicators settlement with LGC Biosearch Applied sciences to speed up manufacturing of uneven siRNA for the therapy of androgenic alopecia. Dr. Lee will current at right this moment’s SMi’s twelfth Annual RNA Therapeutics digital convention. He’ll talk about OLX104C at this occasion. OliX plans to provoke medical trials of OLX104C “by 2022”.
Replace: January 2022 — A brand new South Korean firm named siRNAgen Therapeutics (a subsidiary of Bioneer) is growing a SAMiRNA primarily based hair loss product. SAMiRNA is a brand new kind of siRNA nanoparticle that doesn’t end in innate immune stimulation.
Replace: March 2022 — Bioneer updates us on its new CosmeRNA product. Appears to be like like they may launch it in South Korea and Germany (plus EU) this yr.
“Cosmerna is the world’s first short-interfering RNA (siRNA) gene technology-based practical beauty for assuaging hair loss signs”.
A whole bunch of thousands and thousands of individuals all over the world will take mRNA vaccines through the subsequent a number of years. In impact, this can velocity up scientific progress and trigger many to not fear about long-term unintended effects. Maybe a mistake, however I’ll selfishly not complain an excessive amount of if it accelerates the conclusion of a hair loss remedy.
